Are you already a client or interested in our services? We are happy to help you.
For Private Banking and Professional Solutions
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11For Investment Management:
For Investment Banking:
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United States of America
+1 (0)21 237 601 34Co-manager
Kempen is pleased to announce that it acted as Co-Manager to Galapagos in its USD 345 million public offering
Galapagos is a clinical-stage biotechnology company specialised in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. Its main product is filgotinib, which shows very positive Phase 3 clinical results for rheumatoid arthritis, Crohn's disease and ulcerative colitis and which is partnered with Gilead Sciences. The Galapagos group, including fee-for-service subsidiairy Fidelta, has approximately 675 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, Switzerland, the US and Croatia. In the first half of 2018 Galapagos generated €101.9m in revenue and on 30 Jun 2018 it had €1,067m in cash and cash equivalents.